Veraxa Biotech names Carl von Halem interim CFO, replacing Torsten Bürgermeister

• Veraxa appointed Carl von Halem as interim chief financial officer, replacing Torsten Bürgermeister.
• Management is in late-stage talks with a permanent CFO candidate to support the next phase of expansion and operational growth.
• Von Halem is CFO of Xlife Sciences, where he helped take Veraxa public and worked on the NASDAQ listing process.
• He also serves as managing director of Xlife Science GmbH, with prior experience as co-founder and COO of fintech CommneX.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-007510), on July 10, 2026, and is solely responsible for the information contained therein.